Browsing Tag
Repatha
6 posts
Amgen (NASDAQ: AMGN) expands TrumpRx pricing deal, offers Aimovig and Amjevita at $299
Amgen cuts U.S. drug prices for Aimovig and Amjevita under TrumpRx, citing earlier investments in Ohio and North Carolina. See what this signals for big pharma.
Amgen’s landmark Repatha trial to take center stage at AHA 2025 with major cardiovascular prevention results
Find out how Amgen’s Repatha phase 3 trial is redefining cardiovascular prevention and reshaping investor sentiment at AHA 2025.
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.
Amgen reports strong Q4 growth amid expanding product sales and biotech innovations
Amgen’s revenue growth for the fourth quarter of 2024 exceeded analyst expectations, reflecting the company’s expanding biopharmaceutical portfolio…
FDA approves Amgen’s Repatha for heart attack and stroke prevention
In a significant advancement for cardiovascular disease management, Amgen’s Repatha (evolocumab) has received approval from the U.S. Food…
Amgen’s Repatha proves effective in major cardiovascular outcomes study
Amgen Inc. has achieved a significant milestone with its cholesterol-lowering injection, Repatha (evolocumab), demonstrating a 20% reduction in…